1
|
Kamal MV, Pai SRK, Hari G, Priya K, Godkhindi VM, Pai A, Dikhit PS, Belle VS. In Vitro Cytotoxic Activity and In Vivo Antiproliferative Activity of Ethyl Acetate Fraction of Bunium bulbocastanum Seed Against Prostatic Neoplasia. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, INDIA SECTION B: BIOLOGICAL SCIENCES 2024. [DOI: 10.1007/s40011-024-01583-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 11/09/2023] [Accepted: 03/19/2024] [Indexed: 08/14/2024]
Abstract
AbstractSeveral in vitro investigations of the therapeutic characteristics of B. bulbocastanum have shown that it has cytotoxic, antifungal, and antibacterial effects. It also exhibits antioxidant and anticancer effects. When the ethyl acetate fraction of B. bulbocastanum was examined for its phytochemical composition, it was found to be rich in phenolic compounds and had significant cytotoxic effects on PC-3 cell lines. The prostate length-to-weight ratio was significantly higher in vivo in the ethyl acetate fraction-treated group. Compared to the disease control group, histopathological examination of the ethyl acetate-treated group revealed a reduction in inflammation and malignant lesions, confirming its antiproliferative efficacy. According to serum biochemistry, acid phosphatase and PSA levels in the ethyl acetate fraction treatment group were significantly lower than those in the disease control group. When compared to the disease control group, malondialdehyde levels in the ethyl acetate fraction treatment group were likewise reduced dramatically. However, in the group treated with the ethyl acetate fraction, glutathione levels increased considerably. The ethyl acetate fraction of B. bulbocastanum may have cytotoxic and antiproliferative potential, both in vitro and in vivo.
Collapse
|
2
|
da Silva Junior MM, Capibaribe DM, Avilez ND, Jalalizadeh M, Dias LB, Laranja WW, Guimarães F, Simões FA, Alonso JCC, Rejowski RF, Cintra A, Reis LO. Digital rectal examination impact on PSA derivatives and prostate biopsy triggers: a contemporary study. Int Urol Nephrol 2022; 54:2117-2123. [PMID: 35789453 DOI: 10.1007/s11255-022-03283-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 06/22/2022] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To evaluate the impact of the digital rectal exam (DRE) on PSA measurements and clinical decision-making. METHODS Healthy male volunteers between 50 and 70 years old were recruited during a 30-day public screening program. PSA levels were measured using two different methods (standard enhanced chemiluminescence immunoassay-ECLIA, and novel immunochromatography assay-ICA/rapid PSA) in the same blood sample. Two blood samples were drawn; first before DRE and the second 30-40 min after DRE. The effect of DRE on PSA levels and its impact on clinical decision-making for individual patients were evaluated based on different biopsy trigger cutoffs. RESULTS ECLIA-PSA was measured in 74 participants both pre- and 37 ± 5 min post-DRE, mean age 57.2 ± 8.3 years, and mean prostate volume 33.6 (20-80) cm3. Both total and free ECLIA-PSA increased significantly after DRE (mean increase of 0.47 and 0.26 ng/ml, respectively, both p < 0.001). Different internationally accepted biopsy triggers were reached after DRE only: 5 total PSA > 3 ng/ml, 13 increase > 0.75 ng/ml, 3 PSA density > 0.15, and 1 free/total PSA < 0.18. On two occasions, patients were pushed away from biopsy trigger after DRE due to free/total PSA > 0.18. ICA-PSA was detectable (> 2.0 ng/ml) in 5 of 45 measured samples (11%) before DRE and 13/45 (29%) after DRE, p = 0.0316. Four among five detectable ICA-PSA tests increased after DRE. CONCLUSION Performing DRE immediately before PSA measurement might change the clinical decision-making on a significant number of occasions (roughly 1 in 3); even though the mean increase (0.47 ng/ml) looks deceivingly small. Further studies are required that include gold standard tests (biopsy, or imaging).
Collapse
Affiliation(s)
- Maurício Moreira da Silva Junior
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Diego Moreira Capibaribe
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Natalia Dalsenter Avilez
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Mehrsa Jalalizadeh
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Luiza Bortoloti Dias
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Walker W Laranja
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Fabio Guimarães
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Fabiano A Simões
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - João C C Alonso
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Ronald F Rejowski
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Adriano Cintra
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil.,Paulínia Municipal Hospital, Paulínia, SP, Brazil
| | - Leonardo O Reis
- UroScience, Faculty of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil. .,Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, SP, Brazil. .,Paulínia Municipal Hospital, Paulínia, SP, Brazil.
| |
Collapse
|
3
|
Satcher RL, Zhang XHF. Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nat Rev Cancer 2022; 22:85-101. [PMID: 34611349 DOI: 10.1038/s41568-021-00406-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/02/2021] [Indexed: 12/14/2022]
Abstract
Many cancer types metastasize to bone. This propensity may be a product of genetic traits of the primary tumour in some cancers. Upon arrival, cancer cells establish interactions with various bone-resident cells during the process of colonization. These interactions, to a large degree, dictate cancer cell fates at multiple steps of the metastatic cascade, from single cells to overt metastases. The bone microenvironment may even influence cancer cells to subsequently spread to multiple other organs. Therefore, it is imperative to spatiotemporally delineate the evolving cancer-bone crosstalk during bone colonization. In this Review, we provide a summary of the bone microenvironment and its impact on bone metastasis. On the basis of the microscopic anatomy, we tentatively define a roadmap of the journey of cancer cells through bone relative to various microenvironment components, including the potential of bone to function as a launch pad for secondary metastasis. Finally, we examine common and distinct features of bone metastasis from various cancer types. Our goal is to stimulate future studies leading to the development of a broader scope of potent therapies.
Collapse
Affiliation(s)
- Robert L Satcher
- Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Xiang H-F Zhang
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
| |
Collapse
|
4
|
Schröder SK, Pinoé-Schmidt M, Weiskirchen R. Lipocalin-2 (LCN2) Deficiency Leads to Cellular Changes in Highly Metastatic Human Prostate Cancer Cell Line PC-3. Cells 2022; 11:cells11020260. [PMID: 35053376 PMCID: PMC8773519 DOI: 10.3390/cells11020260] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 01/05/2022] [Accepted: 01/10/2022] [Indexed: 02/01/2023] Open
Abstract
The transporter protein lipocalin-2 (LCN2) also termed neutrophil-gelatinase-associated lipocalin (NGAL) has pleiotropic effects in tumorigenesis in various cancers. Since the precise role of LCN2 in prostate cancer (PCa) is poorly understood, we aimed to elucidate its functions in PCa in vitro. For this purpose, LCN2 was transiently suppressed or permanently depleted in human PC-3 cells using siRNA or CRISPR/Cas9-mediated knockout. Effects of LCN2 suppression on expression of different tumorigenic markers were investigated by Western blot analysis and RT-qPCR. LCN2 knockout cells were analyzed for cellular changes and their ability to cope endoplasmic stress compared to parenteral PC-3 cells. Reduced LCN2 was accompanied by decreased expression of IL-1β and Cx43. In PC-3 cells, LCN2 deficiency leads to reduced proliferation, diminished expression of pro-inflammatory cytokines, lower adhesion, and disrupted F-actin distribution. In addition, IL-1β expression strongly correlated with LCN2 levels. LCN2 knockout cells showed enhanced and sustained activation of unfolded protein response proteins when treated with tunicamycin or cultured under glucose deprivation. Interestingly, an inverse correlation between phosphorylation of eukaryotic initiation factor 2 α subunit (p-eIF2α) and LCN2 expression was observed suggesting that LCN2 triggers protein synthesis under stress conditions. The finding that LCN2 depletion leads to significant phenotypic and cellular changes in PC-3 cells adds LCN2 as a valuable target for the treatment of PCa.
Collapse
|
5
|
Wu L, Shu X, Bao J, Guo X, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W. Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer Res 2019; 79:4592-4598. [PMID: 31337649 DOI: 10.1158/0008-5472.can-18-3997] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 04/21/2019] [Accepted: 07/17/2019] [Indexed: 12/24/2022]
Abstract
Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers of prostate cancer risk, we studied 79,194 cases and 61,112 controls of European ancestry, included in the PRACTICAL/ELLIPSE consortia, using genetic instruments of protein quantitative trait loci for 1,478 plasma proteins. A total of 31 proteins were associated with prostate cancer risk including proteins encoded by GSTP1, whose methylation level was shown previously to be associated with prostate cancer risk, and MSMB, SPINT2, IGF2R, and CTSS, which were previously implicated as potential target genes of prostate cancer risk variants identified in genome-wide association studies. A total of 18 proteins inversely correlated and 13 positively correlated with prostate cancer risk. For 28 of the identified proteins, gene somatic changes of short indels, splice site, nonsense, or missense mutations were detected in patients with prostate cancer in The Cancer Genome Atlas. Pathway enrichment analysis showed that relevant genes were significantly enriched in cancer-related pathways. In conclusion, this study identifies 31 candidates of protein biomarkers for prostate cancer risk and provides new insights into the biology and genetics of prostate tumorigenesis. SIGNIFICANCE: Integration of genomics and proteomics data identifies biomarkers associated with prostate cancer risk.
Collapse
Affiliation(s)
- Lang Wu
- Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii.,Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Xiang Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Jiandong Bao
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | | | - Zsofia Kote-Jarai
- Division of Genetics and Epidemiology, The Institute of Cancer Research, and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Christopher A Haiman
- Department of Preventive Medicine, University of Southern California, Los Angeles, California
| | - Rosalind A Eeles
- Division of Genetics and Epidemiology, The Institute of Cancer Research, and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
| | | |
Collapse
|
6
|
Nakanishi A, Hirata Y. Practically scheduling hormone therapy for prostate cancer using a mathematical model. J Theor Biol 2019; 478:48-57. [PMID: 31202792 DOI: 10.1016/j.jtbi.2019.06.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 05/20/2019] [Accepted: 06/12/2019] [Indexed: 01/26/2023]
Abstract
Hormone therapy is one of the popular therapeutic methods for prostate cancer. Intermittent androgen suppression (IAS) is the method which stops and resumes hormone therapy repeatedly. The efficacy of IAS differs depending on patients; both the cases have been reported where the relapse of cancer happened and did not happen, for the patients who had undergone IAS. For the patients who cannot avoid the relapse of cancer by IAS, we should delay the relapse of cancer as later as possible. Here we compared some practical methods of determining when to stop and restart hormone therapy for IAS using an existing mathematical model of prostate cancer. The method we suggest is to determine the ratio of on-treatment period and off-treatment period sparsely for each cycle, namely the "sparse search." We also compared the performance of the sparse search with the exhaustive search and the model predictive control. We found that the sparse search can find a good treatment schedule without failure, and the computational cost is not so high compared to the exhaustive method. In addition, we focus on the model predictive control (MPC) method which has been applied to the scheduling of IAS in some existing studies. The MPC is computationary efficient, although it does not always find an optimal schedule in the numerical experiments here. We believe that the MPC method might be also promising because of its reasonable computational costs and its possibility of expanding of the model.
Collapse
Affiliation(s)
- Ayako Nakanishi
- Graduate School of Information Science and Technology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
| | - Yoshito Hirata
- Graduate School of Information Science and Technology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan; Mathematics and Informatics Center, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan
| |
Collapse
|
7
|
Wu KJ, Pei XQ, Tian G, Wu DP, Fan JH, Jiang YM, He DL. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian J Androl 2019; 20:173-177. [PMID: 28905815 PMCID: PMC5858103 DOI: 10.4103/aja.aja_34_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level ≥50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan–Meier analysis were used to predict overall survival (OS). In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN <17 weeks (42.83 vs 21.50 weeks, P < 0.001). The time to PSA progression in patients with TTN ≥17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was <17 weeks. We found several factors to be associated with OS, including TTN (hazard ratio [HR]: 3.937, 95% confidence interval [CI]: 1.502–10.309, P = 0.005), PSA level at the diagnosis of cancer (HR: 4.337, 95% CI: 1.616–11.645, P = 0.004), duration of initial androgen deprivation therapy (HR: 2.982, 95% CI: 1.104–8.045, P = 0.031), neutrophil-to-lymphocyte ratio (HR: 3.963, 95% CI: 1.380–11.384, P = 0.011), and total PSA response (Class 1 [<0 response] compared to Class 2 [0–50% response], HR: 3.978, 95% CI: 1.278–12.387, P = 0.017). In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have >50% PSA remission.
Collapse
Affiliation(s)
- Kai-Jie Wu
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Xin-Qi Pei
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Ge Tian
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Da-Peng Wu
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Jin-Hai Fan
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Yu-Mei Jiang
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| | - Da-Lin He
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
| |
Collapse
|
8
|
Lane G, Uloko M, Narayan V, J J Ercole C. The History of Urology at the Minneapolis Veterans Affairs Health Care System. Urology 2018; 123:7-11. [PMID: 30248352 DOI: 10.1016/j.urology.2018.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 08/13/2018] [Accepted: 09/11/2018] [Indexed: 10/28/2022]
Abstract
OBJECTIVE The Section of Urology at the Minneapolis Veteran's Affairs (VA) Medical Center has a long history of contributions to Urology including the Gleason Score, Fuhrman Grading system, testicular tumor marker development and the birth of Endourology. The objective of this manuscript is to compile and present the Urologic history of the Minneapolis VA. METHODS The Urologic literature and institutional records originating from the Minneapolis VA Medical Center from 1946-2017 were reviewed and presented herein. RESULTS The Minneapolis VA Health Care System originated in 1921 and currently employs 5 Urologist who serve over 16,000 veterans per year. Historic achievements from the Minneapolis VA Section of Urology include the development of the Veteran's Affairs Cooperative Research Group (VACURG) which was instrumental to development of the Gleason grading system for prostate cancer in 1965. Additional urologic oncology achievements originating from the Minneapolis VA Section of Urology included the development of the diagnostic utility of tumor markers in testis cancer in 1976 and The Fuhrman Grading System in 1982. Perhaps the greatest contribution to the field of Urology was the birth of Endourology at the Minneapolis VA in the late 1970s under the direction of Dr. Paul Lange. Currently the Minneapolis VA is a premier center for Evidence Based Urology by housing Cochrane Urology and the U.S. Grading of Recommendations Assessment, Development and Evaluation network (US GRADE). CONCLUSION Since 1946, the section of Urology at the Minneapolis VA has contributed basic science, clinical technique and evidence based medicine to the field of Urology while providing care to the nation's veterans.
Collapse
Affiliation(s)
- Giulia Lane
- University of Minnesota, Minneapolis, MN; Minneapolis Veterans Affair Health Care System, Minneapolis, MN.
| | - Maria Uloko
- University of Minnesota, Minneapolis, MN; Minneapolis Veterans Affair Health Care System, Minneapolis, MN
| | - Vikram Narayan
- University of Minnesota, Minneapolis, MN; Minneapolis Veterans Affair Health Care System, Minneapolis, MN
| | - Cesar J J Ercole
- University of Minnesota, Minneapolis, MN; Minneapolis Veterans Affair Health Care System, Minneapolis, MN
| |
Collapse
|
9
|
Yao J, Wang Y, Dai Y, Liu CC. Bioconjugated, Single-Use Biosensor for the Detection of Biomarkers of Prostate Cancer. ACS OMEGA 2018; 3:6411-6418. [PMID: 30023946 PMCID: PMC6044577 DOI: 10.1021/acsomega.8b00634] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 06/05/2018] [Indexed: 05/20/2023]
Abstract
Prostate cancer is prevalent among cancers in men. A simple method for screening of reliable biomarkers is pivotal for early detection of prostate cancer. Prostate-specific antigen (PSA) has been a commonly used biomarker for prostate cancer, in spite of its false-positive limitation. On the other hand, alpha-methylacyl-CoA racemase (AMACR), a metabolic enzyme, has been proven to be a highly expressed biomarker in prostate cancer cells. Therefore, a method or tool, which can detect either PSA or AMACR or both simply, cost effectively, and with high sensitivity and selectivity is desirable. We describe a novel bioconjugated, single-use biosensor capable of detecting both PSA and AMACR antigens in undiluted human serum. The preparation of the biosensor by the bioconjugation mechanism occurred within a day, which could be completed prior to actual testing. The effectiveness of the bioconjugation mechanism and the coverage of the electrode surface of the biosensor were experimentally assessed. Measurements of PSA and AMACR antigens and the specificity of the biosensor were carried out using differential pulse voltammetry. This biosensor was single-use and cost-effective and required a small quantity of test medium and relatively short preparation time, providing a very attractive biosensor for the detection of the biomarkers of prostate cancer.
Collapse
Affiliation(s)
- Jiwei Yao
- Department
of Chemical & Biomolecular Engineering and Electronics Design
Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States
| | - Yuan Wang
- Department
of Chemical & Biomolecular Engineering and Electronics Design
Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States
| | - Yifan Dai
- Department
of Chemical & Biomolecular Engineering and Electronics Design
Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States
| | - Chung Chiun Liu
- Department
of Chemical & Biomolecular Engineering and Electronics Design
Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States
- E-mail: . Phone: 216-368-2935 (C.C.L.)
| |
Collapse
|
10
|
Ceriani L, Giovanella L, Salvadore M, Bono AV, Roncari G. Tissue Polypeptide-Specific Antigen (Tps) Immunoassay in the Diagnosis and Clinical Staging of Prostatic Carcinoma. Comparison with Prostate-Specific Antigen (Psa). Int J Biol Markers 2018; 12:27-34. [PMID: 9176715 DOI: 10.1177/172460089701200106] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This experimental study investigated the potential role of Tissue Polypeptide-Specific Antigen (TPS) in comparison with Prostate-Specific Antigen (PSA) in the diagnosis and the clinical and pathological staging of prostate cancer. Serum TPS and PSA levels were determined in 128 patients (pts) with benign prostatic hypertrophy (BPH; Group 1) and in 92 pts with prostate cancer (Group 2). TPS was also measured in a control group of 100 healthy subjects. Normal cutoff values of 85 U/l for TPS and 4 ng/ml for PSA were determined on the basis of ROC curve analysis. The sensitivity, specificity and accuracy in the diagnosis of prostate cancer were 49%, 95% and 76% for TPS, and 84%, 90% and 87% for PSA. The combination of the two markers provided a higher accuracy (88%), improving the sensitivity of PSA, since 47% of patients with normal PSA had pathological levels of TPS. TPS showed an increase in sensitivity from low to higher stages of disease and, in patients with skeletal involvement, from small to larger numbers of bone metastases (Kruskal Wallis p < 0.0001). Nevertheless, TPS serum levels are not useful in the clinical staging of prostate cancer as they have a poorer performance than PSA. TPS was ineffective (ROC curve area=0.68) in predicting extraprostatic disease and demonstrated a reduced ability (area = 0.78) to identify skeletal involvement. Moreover, the combination of the two markers did not significantly improve the performance of PSA alone. The serum concentration of TPS in patients with localized tumors was not related to the degree of tumor cell differentiation evaluated by the Gleason score. Conclusion Our preliminary experience suggests that TPS in association with PSA may be useful at the time of diagnosis of prostate cancer. However, these preliminary data have to be confirmed by larger clinical trials and the role of this association in the clinical setting needs to be analyzed with an adequate evaluation of the cost-effectiveness ratio.
Collapse
Affiliation(s)
- L Ceriani
- Department of Nuclear Medicine, Regional Hospital, Varese, Italy
| | | | | | | | | |
Collapse
|
11
|
Mione R, Barichello M, Sartorello P, Leon A, Barioli P, Gion M. Third-Generation Psa: Ultrasensitive or Ultraprecise Assay? Int J Biol Markers 2018; 10:229-33. [PMID: 8750651 DOI: 10.1177/172460089501000408] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The ultrasensitive PSA assay has been recently acknowledged as a useful tool for the monitoring of patients prostatectomized for prostatic cancer. We have evaluated a commercially available ultrasensitive PSA assay (Immulite Third Generation PSA - DPC - Los Angeles CA) in comparison with the routinely used PSA (Immulite PSA - DPC - Los Angeles CA). When evaluated with different approaches, the analytical sensitivity of ultrasensitive PSA ranged between 0.0029 and 0.0038 ng/ml. The biological detection limit was 0.0098 ng/ml. Dilution of samples with low PSA levels showed a good recovery (from 88 to 113%) up to 1:128 dilution factor (final PSA levels ranging from 0.004 to 0.016 ng/ml in different samples). The assay precision was excellent in the low dose range, the highest interassay interadjustment CV among replicates being 5.84% when assaying serum samples with PSA lower than 1.0 ng/ml. Besides its role in the follow-up of prostatectomized patients, the evaluated ultrasensitive PSA could be reliably used for the detection of clinically meaningful PSA variations in the low dose range, and it could therefore be a candidate for the assessment of PSA velocity.
Collapse
Affiliation(s)
- R Mione
- Center for the Study of Biological Markers of Malignancy, National Center for the Application of Biotechnologies in Oncology, Venezia, Italy
| | | | | | | | | | | |
Collapse
|
12
|
Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Orsola A, Planas J, Catalán R, Reventós J. Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer. Int J Biol Markers 2018; 20:209-16. [PMID: 16398402 DOI: 10.1177/172460080502000403] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. In a group of 185 metastatic prostate cancer patients who received androgen deprivation therapy serum PSA was determined every three months until AIP occurred. Multiple regression analysis was performed to define independent clinical and PSA-related predictors of AIP. AIP was assumed to be present after two consecutive increases in serum PSA after the PSA nadir. Independent predictors of the duration of AIP-free survival (less than 12 months versus more than 12 months) were the extent of bone involvement (six or fewer hot spots versus more than six) with an odds ratio (O.R.) of 3.95, Gleason score (7 or less versus more than 7) with an O.R. of 3.47, and PSA nadir (2 μg/L or less versus more than 2 μg/L) with an O.R. of 14.63. AIP was independently predicted by the extent of bone involvement with an O.R. of 1.72, Gleason score with an O.R. of 1.74, PSA nadir with an O.R. of 3.22, and time to reach the PSA nadir (9 months or less versus more than 9 months) with an O.R. of 2.84. When patients were stratified according to these predictors, those with three good prognostic factors had a median AIP-free survival of 58 months while those with two, one or no good prognostic factors had a median AIP-free survival of 19 months, 12 months and 7 months, respectively. We conclude that the PSA nadir seems to be a good predictor of AIP in patients with metastatic prostate cancer after androgen deprivation therapy. Time to PSA nadir, extent of bone involvement and Gleason score are also independent predictors. The combination of these prognostic factors allows to stratify metastatic prostate cancer patients for the prediction of AIP.
Collapse
Affiliation(s)
- J Morote
- Department of Urology, Vail d'Hebron University Hospital, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Jia X, Chen J, Sun S, Yang W, Yang S, Shah P, Hoti N, Veltri B, Zhang H. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics 2017; 16:2989-2996. [PMID: 27749016 DOI: 10.1002/pmic.201500506] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 09/08/2016] [Accepted: 10/12/2016] [Indexed: 01/24/2023]
Abstract
Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood prostate-specific antigen test has facilitated early detection and intervention of prostate cancer. However, blood prostate-specific antigen levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients using LC-MS/MS, with the aim of identifying effective urinary prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. A total of 2923 unique glycosite-containing peptides were identified. Glycoproteomic comparison on urine and tissues from aggressive and non-aggressive prostate cancers as well as sera from prostate cancer patients revealed that the majority of AG prostate cancer associated glycoproteins were more readily detected in patient's urine than serum samples. Our data collectively indicate that urine provides a potential source for biomarker testing in patients with AG prostate cancer.
Collapse
Affiliation(s)
- Xingwang Jia
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.,Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, P. R. China
| | - Jing Chen
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Shisheng Sun
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Weiming Yang
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Shuang Yang
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Punit Shah
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Naseruddin Hoti
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| | - Bob Veltri
- Department of Urology, Johns Hopkins University, Baltimore, MD, USA
| | - Hui Zhang
- Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
14
|
Straseski JA, Whale C, Wilson A, Strathmann FG. The significance of reporting to the thousandths place: Figuring out the laboratory limitations. Pract Lab Med 2017; 7:1-5. [PMID: 28856212 PMCID: PMC5575378 DOI: 10.1016/j.plabm.2016.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Revised: 09/02/2016] [Accepted: 11/07/2016] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVES A request to report laboratory values to a specific number of decimal places represents a delicate balance between clinical interpretation of a true analytical change versus laboratory understanding of analytical imprecision and significant figures. Prostate specific antigen (PSA) was used as an example to determine if an immunoassay routinely reported to the hundredths decimal place based on significant figure assessment in our laboratory was capable of providing analytically meaningful results when reported to the thousandths places when requested by clinicians. DESIGN AND METHODS Results of imprecision studies of a representative PSA assay (Roche MODULAR E170) employing two methods of statistical analysis are reported. Sample pools were generated with target values of 0.01 and 0.20 μg/L PSA as determined by the E170. Intra-assay imprecision studies were conducted and the resultant data were analyzed using two independent statistical methods to evaluate reporting limits. RESULTS These statistical methods indicated reporting results to the thousandths place at the two assessed concentrations was an appropriate reflection of the measurement imprecision for the representative assay. This approach used two independent statistical tests to determine the ability of an analytical system to support a desired reporting level. Importantly, data were generated during a routine intra-assay imprecision study, thus this approach does not require extra data collection by the laboratory. CONCLUSIONS Independent statistical analysis must be used to determine appropriate significant figure limitations for clinically relevant analytes. Establishing these limits is the responsibility of the laboratory and should be determined prior to providing clinical results.
Collapse
Affiliation(s)
- Joely A Straseski
- Department of Pathology, University of Utah, Salt Lake City, UT, United States.,ARUP Laboratories, Salt Lake City, UT, United States
| | - Casey Whale
- ARUP Laboratories, Salt Lake City, UT, United States
| | - Andrew Wilson
- Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT, United States
| | - Frederick G Strathmann
- Department of Pathology, University of Utah, Salt Lake City, UT, United States.,ARUP Laboratories, Salt Lake City, UT, United States
| |
Collapse
|
15
|
Abstract
BACKGROUND The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. METHODS A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. CONCLUSIONS With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
Collapse
Affiliation(s)
- Sharanjot Saini
- Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA.
- University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
16
|
Faruq O, Vecchione A. microRNA: Diagnostic Perspective. Front Med (Lausanne) 2015; 2:51. [PMID: 26284247 PMCID: PMC4523054 DOI: 10.3389/fmed.2015.00051] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 07/17/2015] [Indexed: 12/15/2022] Open
Abstract
Biomarkers are biological measures of a biological state. An ideal marker should be safe and easy to measure, cost efficient, modifiable with treatment, and consistent across gender and ethnic groups. To date, none of the available biomarkers satisfy all of these criteria. In addition, the major limitations of these markers are low specificity, sensitivity, and false positive results. Recently identified, microRNAs (miRNAs) are endogenous, evolutionarily conserved small non-coding RNA (about 22–25 nt long), also known as micro-coordinators of gene expression, which have been shown to be an effective tools to study the biology of diseases and to have great potential as novel diagnostic and prognostic biomarkers with high specificity and sensitivity. In fact, it has been demonstrated that miRNAs play a pivotal role in the regulation of a wide range of developmental and physiological processes and their deficiencies have been related to a number of disease. In addition, miRNAs are stable and can be easily isolated and measured from tissues and body fluids. In this review, we provide a perspective on emerging concepts and potential usefulness of miRNAs as diagnostic markers, emphasizing the involvement of specific miRNAs in particular tumor types, subtypes, cardiovascular diseases, diabetes, infectious diseases, and forensic test.
Collapse
Affiliation(s)
- Omar Faruq
- Division of Pathology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Ospedale Santo Andrea, Sapienza University of Rome , Rome , Italy
| | - Andrea Vecchione
- Division of Pathology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Ospedale Santo Andrea, Sapienza University of Rome , Rome , Italy
| |
Collapse
|
17
|
Kong HY, Byun J. Emerging roles of human prostatic Acid phosphatase. Biomol Ther (Seoul) 2014; 21:10-20. [PMID: 24009853 PMCID: PMC3762301 DOI: 10.4062/biomolther.2012.095] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Revised: 01/10/2013] [Accepted: 01/14/2013] [Indexed: 11/21/2022] Open
Abstract
Prostate cancer is one of the most prevalent non-skin related cancers. It is the second leading cause of cancer deaths among males in most Western countries. If prostate cancer is diagnosed in its early stages, there is a higher probability that it will be completely cured. Prostatic acid phosphatase (PAP) is a non-specific phosphomonoesterase synthesized in prostate epithelial cells and its level proportionally increases with prostate cancer progression. PAP was the biochemical diagnostic mainstay for prostate cancer until the introduction of prostate-specific antigen (PSA) which improved the detection of early-stage prostate cancer and largely displaced PAP. Recently, however, there is a renewed interest in PAP because of its usefulness in prognosticating intermediate to high-risk prostate cancers and its success in the immunotherapy of prostate cancer. Although PAP is believed to be a key regulator of prostate cell growth, its exact role in normal prostate as well as detailed molecular mechanism of PAP regulation is still unclear. Here, many different aspects of PAP in prostate cancer are revisited and its emerging roles in other environment are discussed.
Collapse
Affiliation(s)
- Hoon Young Kong
- Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, Yongin 448-701, Republic of Korea
| | | |
Collapse
|
18
|
Hoeh MP, Deane LA. PSA Screening: A Discussion Based on the USPSTF Recommendations and the AUA and EAU Guidelines. JOURNAL OF MEN'S HEALTH 2014. [DOI: 10.1089/jomh.2014.3502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Thapar R, Titus MA. Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer. ACTA ACUST UNITED AC 2014; 2:53-69. [PMID: 25632377 DOI: 10.2174/2213235x02666140301002510] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Cancer is a metabolic disease. Cancer cells, being highly proliferative, show significant alterations in metabolic pathways such as glycolysis, respiration, the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, lipid metabolism, and amino acid metabolism. Metabolites like peptides, nucleotides, products of glycolysis, the TCA cycle, fatty acids, and steroids can be an important read out of disease when characterized in biological samples such as tissues and body fluids like urine, serum, etc. The cancer metabolome has been studied since the 1960s by analytical techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. Current research is focused on the identification and validation of biomarkers in the cancer metabolome that can stratify high-risk patients and distinguish between benign and advanced metastatic forms of the disease. In this review, we discuss the current state of prostate cancer metabolomics, the biomarkers that show promise in distinguishing indolent from aggressive forms of the disease, the strengths and limitations of the analytical techniques being employed, and future applications of metabolomics in diagnostic imaging and personalized medicine of prostate cancer.
Collapse
Affiliation(s)
- Roopa Thapar
- Department of Biochemistry and Cell Biology, Rice University, Houston, TX 77251-1892, USA
| | - Mark A Titus
- Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA
| |
Collapse
|
20
|
Abstract
This article updates advances in prostate cancer screening based on prostate-specific antigen, its derivatives, and human kallikrein markers. Many men are diagnosed with indolent disease not requiring treatment. Although there is evidence of a survival benefit from screening, the numbers needed to screen and treat remain high. There is risk of exposing men to the side effects of treatment for nonthreatening disease. A screening test is needed with sufficiently good performance characteristics to detect disease at an early stage so treatment may be offered with curative intent, while reducing the number of negative or unnecessary biopsies.
Collapse
Affiliation(s)
- Richard J Bryant
- Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK
| | - Hans Lilja
- Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK; Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue (Mailbox 213), New York, NY 10065, USA; Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, 1275 York Avenue (Mailbox 213), New York, NY 10065, USA; Department of Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, 1275 York Avenue (Mailbox 213), New York, NY 10065, USA.
| |
Collapse
|
21
|
Abstract
Prostate cancer (PCa), a highly heterogeneous disease, is the one of the leading cause of morbidity and mortality in the developed countries. Historically used biomarkers such as prostatic acid phosphatase (PAP), serum prostate-specific antigen (PSA), and its precursor have not stood the challenge of sensitivity and specificity. At present, there is need to re-evaluate the approach to diagnose and monitor PCa. To this end, molecular markers that can accurately identify men with PCa at an early stage, and those who would benefit from early therapeutic intervention, are the need of the hour. There has been unprecedented progress in the development of new PCa biomarkers through advancements in proteomics, tissue DNA and protein/RNA microarray, identification of microRNA, isolation of circulating tumor cells, and tumor immunohistochemistry. This review will examine the current status of prostate cancer biomarkers with emphasis on emerging biomarkers by evaluating their diagnostic and prognostic potentials.
Collapse
Affiliation(s)
- Tapan Bhavsar
- Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | | | | |
Collapse
|
22
|
Malati T, Kumari GR, Murthy PVLN, Reddy CR, Prakash BS. Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian J Clin Biochem 2012; 21:34-40. [PMID: 23105567 DOI: 10.1007/bf02913064] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Prostate Specific Antigen (PSA) has emerged as the most applicable and important tumor marker for carcinoma prostate. In the present study PSA was determined in serum of healthy subjects, patients of benign prostate hypertrophy (BPH) and Carcinoma Prostate (Ca-P) to evaluate its diagnostic efficiency in day to day management of prostate cancer patients and in differentiating patients of early prostate cancer from those with BPH. Receiver operating characteristic curve (ROC) revealed 2 ng/ml and 10 ng/ml cut off serum PSA level for BPH and untreated carcinoma prostate patients (Ca-P). An extremely significant increase (P<0.0001) was observed in mean PSA concentration in BPH patients and adenocarcinoma prostate patients when compared to healthy males. Clinical relevance of PSA was highlighted by a case study of cancer patient prior to any therapy till death.
Collapse
Affiliation(s)
- T Malati
- Department of Biochemistry, Nizam's Institute of Medical Sciences, Panjagutta, 500082 Hyderabad, Andhra Pradesh India
| | | | | | | | | |
Collapse
|
23
|
Malati T, Kumari GR. Racial and ethnic variation of PSA in global population: Age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian J Clin Biochem 2012; 19:132-7. [PMID: 23105445 DOI: 10.1007/bf02872408] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The serum PSA is universally accepted as the useful and clinically relevant tumor marker for monitoring therapy and identifying early recurrence in patients of carcinoma prostate throughout the world. However, application of serum PSA is limited to screening for early adenocarcinoma prostate among males above fifty years of age.Serum PSA concentration varies from one population to another in different parts of the world. Many groups of workers have selected 4 ng/ml of serum PSA as upper limit of normal range without giving due consideration for age specific increase in serum PSA. There is no single report available on normal decade wise age specific reference intervals for serum PSA in Indian males.The present study is undertaken to establish age specific reference intervals in healthy Indian males from 20-89 years belonging to subpopulation of Andhra Pradesh from South India. Our results revealed lowest concentration of 95 percentile serum PSA in Indian males compared to other populations globally. Contrary to this, healthy Afro Americans were found to have highest concentration of serum PSA compared to all other populations.
Collapse
Affiliation(s)
- T Malati
- Department of Biochemistry, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad
| | | |
Collapse
|
24
|
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4:127rv3. [PMID: 22461644 DOI: 10.1126/scitranslmed.3003180] [Citation(s) in RCA: 332] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago, prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA has proven controversial as a screening assay owing to several inherent limitations. The next wave of prostate cancer biomarkers has emerged, introducing new assays in serum and urine that may supplement or, in time, replace PSA because of their higher cancer specificity. This expanding universe of biomarkers has been facilitated, in large part, by new genomic technologies that have enabled an unbiased look at cancer biology. Such efforts have produced several notable success stories that involve rapidly moving biomarkers from the bench to the clinic. However, biomarker research has centered on disease diagnostics, rather than prognosis and prediction, which would address disease management. The development of biomarkers to stratify risk of prostate cancer aggressiveness at the time of screening remains the greatest unmet clinical need in prostate cancer. We review the current state of prostate cancer biomarker research, including the PSA revolution, its impact on early cancer detection, the recent advances in biomarker discovery, and the future efforts that promise to improve clinical management of this disease.
Collapse
Affiliation(s)
- John R Prensner
- Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | | | | | | |
Collapse
|
25
|
Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol 2012; 53:607-13. [PMID: 23060997 PMCID: PMC3460002 DOI: 10.4111/kju.2012.53.9.607] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 06/18/2012] [Indexed: 12/03/2022] Open
Abstract
Purpose To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer. Materials and Methods One hundred thirty-one patients with metastatic, hormone-sensitive prostate cancer treated with MAB at our institution were included in this study. Patients' characteristics, PSA at MAB initiation, PSA nadir, time to PSA nadir (TTN), and PSA decline were analyzed by using univariate and multivariate analysis. Results At a median follow-up of 30 months, 97 patients (74.0%) showed disease progression and 65 patients (49.6%) died. Fifty-nine patients (45.0%) died from prostate cancer. In the univariate analysis, PSA at MAB initiation, PSA nadir, TTN, and PSA decline were significant predictors of progression-free survival. Also, PSA nadir, TTN, and PSA decline were significant predictors of cancer-specific survival. In the multivariate analysis, higher PSA nadir (≥0.2 ng/ml) and shorter TTN (<8 months) were independent predictors of shorter progression-free and cancer-specific survival. In the combined analysis of PSA nadir and TTN, patients with higher PSA nadir and shorter TTN had the worst progression-free survival (hazard ratio [HR], 14.098; p<0.001) and cancer-specific survival (HR, 14.050; p<0.001) compared with those with lower PSA nadir and longer TTN. Conclusions Our results suggest that higher PSA nadir level and shorter TTN following MAB are associated with higher risk of disease progression and poorer survival in patients with metastatic, hormone-sensitive prostate cancer. Furthermore, these two variables have a synergistic effect on the outcome.
Collapse
Affiliation(s)
- Seok Young Hong
- Department of Urology, Ajou University School of Medicine, Suwon, Korea
| | | | | | | | | |
Collapse
|
26
|
Motion JM, Nguyen J, Szoka FC. Phosphatase-triggered fusogenic liposomes for cytoplasmic delivery of cell-impermeable compounds. Angew Chem Int Ed Engl 2012; 51:9047-51. [PMID: 22887437 PMCID: PMC3470804 DOI: 10.1002/anie.201204198] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Indexed: 11/10/2022]
Abstract
License to fuse! A phosphorylated fusion peptide can mediate membrane fusion when the phosphates (green triangles, see scheme) are removed by phosphatases (blue spheres), delivering the contents of the liposome into the cytosol. This phosphatase-triggered approach may be useful to create target-specific lipid nanocarriers.
Collapse
Affiliation(s)
- J.P. Michael Motion
- Joint Graduate Group in Bioengineering, University of California, Berkeley, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94143-0912 (USA)
| | - Juliane Nguyen
- Joint Graduate Group in Bioengineering, University of California, Berkeley, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94143-0912 (USA)
| | - Francis C. Szoka
- Joint Graduate Group in Bioengineering, University of California, Berkeley, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94143-0912 (USA)
| |
Collapse
|
27
|
Motion JPM, Nguyen J, Szoka FC. Phosphatase-Triggered Fusogenic Liposomes for Cytoplasmic Delivery of Cell-Impermeable Compounds. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201204198] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
28
|
Pal RP, Maitra NU, Mellon JK, Khan MA. Defining prostate cancer risk before prostate biopsy. Urol Oncol 2012; 31:1408-18. [PMID: 22795499 DOI: 10.1016/j.urolonc.2012.05.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Revised: 05/29/2012] [Accepted: 05/31/2012] [Indexed: 12/24/2022]
Abstract
Prostate cancer is the most commonly diagnosed cancer in men. At present, patients are selected for prostate biopsy on the basis of age, serum prostate specific antigen (PSA), and prostatic digital rectal examination (DRE) findings. However, due to limitations in the use of PSA and DRE, many patients undergo unnecessary prostate biopsy. A further problem arises as many patients are diagnosed and treated for indolent disease. This review of the literature highlights the strengths and weaknesses of existing methods of prebiopsy risk stratification and evaluates promising serum, urine, and radiologic prostate cancer biomarkers, which may improve risk stratification for prostate biopsy in the future.
Collapse
Affiliation(s)
- Raj P Pal
- University Hospitals of Leicester NHS Trust, Department of Urology, Leicester General Hospital, Leicester, LE5 4PW, UK.
| | | | | | | |
Collapse
|
29
|
Lin HC, Wu HC, Chang CH, Li TC, Liang WM, Wang JYW. Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment. BMC Med Inform Decis Mak 2011; 11:16. [PMID: 21385459 PMCID: PMC3068074 DOI: 10.1186/1472-6947-11-16] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2010] [Accepted: 03/08/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND A real-time clinical decision support system (RTCDSS) with interactive diagrams enables clinicians to instantly and efficiently track patients' clinical records (PCRs) and improve their quality of clinical care. We propose a RTCDSS to process online clinical informatics from multiple databases for clinical decision making in the treatment of prostate cancer based on Web Model-View-Controller (MVC) architecture, by which the system can easily be adapted to different diseases and applications. METHODS We designed a framework upon the Web MVC-based architecture in which the reusable and extractable models can be conveniently adapted to other hospital information systems and which allows for efficient database integration. Then, we determined the clinical variables of the prostate cancer treatment based on participating clinicians' opinions and developed a computational model to determine the pretreatment parameters. Furthermore, the components of the RTCDSS integrated PCRs and decision factors for real-time analysis to provide evidence-based diagrams upon the clinician-oriented interface for visualization of treatment guidance and health risk assessment. RESULTS The resulting system can improve quality of clinical treatment by allowing clinicians to concurrently analyze and evaluate the clinical markers of prostate cancer patients with instantaneous clinical data and evidence-based diagrams which can automatically identify pretreatment parameters. Moreover, the proposed RTCDSS can aid interactions between patients and clinicians. CONCLUSIONS Our proposed framework supports online clinical informatics, evaluates treatment risks, offers interactive guidance, and provides real-time reference for decision making in the treatment of prostate cancer. The developed clinician-oriented interface can assist clinicians in conveniently presenting evidence-based information to patients and can be readily adapted to an existing hospital information system and be easily applied in other chronic diseases.
Collapse
Affiliation(s)
- Hsueh-Chun Lin
- Department of Health Risk Management, School of Public Health, China Medical University, 91 Hsueh-Shi Road, Taichung 40402, Taiwan.
| | | | | | | | | | | |
Collapse
|
30
|
Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010; 1:150-77. [PMID: 20975847 PMCID: PMC2962426 DOI: 10.7150/jca.1.150] [Citation(s) in RCA: 141] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2010] [Accepted: 10/04/2010] [Indexed: 01/08/2023] Open
Abstract
Prostate cancer is the most frequently diagnosed malignancy in American men, and a more aggressive form of the disease is particularly prevalent among African Americans. The therapeutic success rate for prostate cancer can be tremendously improved if the disease is diagnosed early. Thus, a successful therapy for this disease depends heavily on the clinical indicators (biomarkers) for early detection of the presence and progression of the disease, as well as the prediction after the clinical intervention. However, the current clinical biomarkers for prostate cancer are not ideal as there remains a lack of reliable biomarkers that can specifically distinguish between those patients who should be treated adequately to stop the aggressive form of the disease and those who should avoid overtreatment of the indolent form. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. A biomarker reveals further information to presently existing clinical and pathological analysis. It facilitates screening and detecting the cancer, monitoring the progression of the disease, and predicting the prognosis and survival after clinical intervention. A biomarker can also be used to evaluate the process of drug development, and, optimally, to improve the efficacy and safety of cancer treatment by enabling physicians to tailor treatment for individual patients. The form of the prostate cancer biomarkers can vary from metabolites and chemical products present in body fluid to genes and proteins in the prostate tissues. Current advances in molecular techniques have provided new tools facilitating the discovery of new biomarkers for prostate cancer. These emerging biomarkers will be beneficial and critical in developing new and clinically reliable indicators that will have a high specificity for the diagnosis and prognosis of prostate cancer. The purpose of this review is to examine the current status of prostate cancer biomarkers, with special emphasis on emerging markers, by evaluating their diagnostic and prognostic potentials. Both genes and proteins that reveal loss, mutation, or variation in expression between normal prostate and cancerous prostate tissues will be covered in this article. Along with the discovery of prostate cancer biomarkers, we will describe the criteria used when selecting potential biomarkers for further development towards clinical use. In addition, we will address how to appraise and validate candidate markers for prostate cancer and some relevant issues involved in these processes. We will also discuss the new concept of the biomarkers, existing challenges, and perspectives of biomarker development.
Collapse
Affiliation(s)
- Chikezie O Madu
- Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
| | | |
Collapse
|
31
|
Patanè S. Prostate-specific antigen kallikrein and the heart. World J Cardiol 2009; 1:23-5. [PMID: 21160572 PMCID: PMC2999037 DOI: 10.4330/wjc.v1.i1.23] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2009] [Revised: 12/27/2009] [Accepted: 12/28/2009] [Indexed: 02/06/2023] Open
Abstract
Currently, there is growing interest regarding prostate-specific antigen (PSA) and the cardiovascular system. Increased PSA serum levels have been reported after prolonged cardiopulmonary resuscitation, cardiac surgery, extracorporeal cardiopulmonary bypass, acute myocardial infarction (AMI) and coronary artery stenting. The possible role of PSA in cardiac events has been questioned due to the finding of PSA decrease during AMI and by the correlation of variation in PSA levels with coronary lesions and occurrence of major adverse cardiac events. Complexed PSA forms and uncomplexed PSA forms are observed in the bloodstream but the increasing formation of irreversible bound PSA seems to be a crucial finding during AMI. Large studies need to be carried out to confirm these preliminary results and to elucidate unclear aspects. These findings present many potential directions for future research including the role of uncomplexed forms of PSA, the possible distribution of PSA in the heart, the relative expression levels in heart disease states, the mode of expression regulation and other potential specific substrates. The journey of PSA investigation could be longer than initially expected.
Collapse
Affiliation(s)
- Salvatore Patanè
- Salvatore Patanè, Cardiology Unit, New Cutroni Zodda Hospital, Barcellona P.d.G(Me), Provincial Health Authority of Messina, 98051 Barcellona Pozzo di Gotto(Me), Italy
| |
Collapse
|
32
|
|
33
|
Affiliation(s)
- Danil V. Makarov
- The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland; ; ;
| | - Stacy Loeb
- The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland; ; ;
| | - Robert H. Getzenberg
- The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland; ; ;
| | - Alan W. Partin
- The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland; ; ;
| |
Collapse
|
34
|
van Renterghem K, Van Koeveringe G, Van Kerrebroeck P. Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link? Int Urol Nephrol 2007; 39:1107-13. [PMID: 17602307 DOI: 10.1007/s11255-007-9209-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2006] [Accepted: 03/02/2007] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To determine the role of pressure flowmetry in patients without bothersome lower urinary tract symptoms (LUTS), rising prostate-specific antigen (PSA) levels and diagnosed as having clinical benign prostatic hyperplasia (BPH) after negative (multiple) extended multi-site biopsy. METHODS The study enrolled patients with minor LUTS who were referred to our urological practice by their general practitioner because of a rising PSA level (>/=4 ng/ml). After exclusion of clinical prostatic carcinoma by digital rectal examination and transrectal ultrasound, all patients underwent at least one set of extended multi-site biopsies to exclude T1c prostate cancer. Patients with negative biopsies (clinical BPH) were subjected to pressure flowmetry whereafter those with bladder outlet obstruction underwent TURP. RESULTS The study included 82 patients, with a mean age of 64.8 years (50.2-78.2 years), satisfying the inclusion criteria. Urodynamic analysis showed that all patients had bladder outlet obstruction. After TURP, eight patients (9.8%) were diagnosed as having histologically proven prostate cancer; 74 patients (90.2%) were diagnosed as having BPH. Patients of the BPH group had a mean preoperative PSA level of 8.8 ng/ml (4.3-25.8 ng/ml) and a mean international prostate symptom score of 8.8 (2-18). The mean detrusor pressure at maximum flow in BPH patients was 89.5 cmH(2)O (20-200 cmH(2)O). CONCLUSIONS An increased PSA in patients with minor or no LUTS, clinical BPH and negative extended multi-site prostate biopsy is strongly correlated to bladder outlet obstruction. Therefore, patients with these characteristics should be treated with TURP.
Collapse
|
35
|
Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249:30-9. [PMID: 17258389 DOI: 10.1016/j.canlet.2006.12.022] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2006] [Accepted: 12/14/2006] [Indexed: 11/23/2022]
Abstract
Currently, in the United States (US), most prostate cancers are diagnosed through screening with digital rectal examination (DRE) and measurement of serum prostate-specific antigen (PSA). The serum PSA level correlates directly with prostate cancer risk and aggressiveness, as well as the outcomes after treatment. PSA testing is also useful in monitoring patients for tumor recurrence after treatment. PSA testing has limited specificity for prostate cancer detection, and its appropriate clinical application has been the topic of debate. Accordingly, several variations on the PSA measurement have emerged as useful adjuncts for prostate cancer screening. These take into consideration additional factors, such as the proportion of different PSA isoforms (free PSA, complexed PSA, pro-PSA and B PSA), the prostate volume (PSA density), and the rate of change in PSA levels over time (PSA velocity or PSA doubling time). Widespread PSA screening is associated with a 75% reduction in the proportion of men who present with metastatic disease since 1985-89 in the US and a 32.5% reduction in the age-adjusted prostate cancer mortality rate through 2003. The history and evidence underlying each of these parameters are reviewed in the following article.
Collapse
Affiliation(s)
- Stacy Loeb
- Department of Urology, Georgetown University School of Medicine, Washington, DC, United States
| | | |
Collapse
|
36
|
Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol 2007; 14:406-11. [PMID: 17511722 DOI: 10.1111/j.1442-2042.2006.01729.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To report the results from an Iranian large population-based randomized study of screening using prostate-specific antigen (PSA) to detect prostate cancer. MATERIALS AND METHODS A total of 3758 Iranian men older than 40 years were mass checked by PSA-based screening. Men with an abnormal digital rectal examination (DRE) and serum total PSA level of greater than 4 ng/mL, underwent transrectal ultrasonography (TRUS)-guided extended prostate biopsy. RESULTS The PSA value (mean +/- standard deviation, SD) in all men without prostate cancer was 1.6 +/- 1.1 ng/mL and in those with cancer 18 +/- 44.8 ng/mL (P = 0.001). PSA values increased with age. In those aged 40-49, 50-59, 60-69 and > or = 70 years, the mean +/- SD PSA values were 1.3 +/- 0.7, 1.4 +/- 0.8, 1.8 +/- 1 and 2.2 +/- 1.6 ng/mL, respectively. Among the screened men, 323 (8.6%) had a serum PSA concentration greater than 4 ng/mL. Of patients who underwent prostate biopsy (230, 71.2%), 129 (positive predictive value, 56.1%) had prostate cancer. Additionally, nine cancers were detected among 16 patients with PSA of less than 4 ng/mL who had a doubtful DRE finding. The overall cancer detection rate was 3.6%; 1.4% at 40-49, 1.6% at 50-59, 4.2% at 60-69 and 12.9% at >/=70 years. Conventional systematic sextant biopsies, which accounted for six of the 10 cores in our biopsy scheme, detected 98 (71%) of the cancers. CONCLUSIONS The Iranian male population develops prostate cancer quite commonly if their serum PSA levels are greater than 4.0 ng/mL. In this study, 65.9% of the detected cancers were clinically significant. The conventional systematic sextant technique may be inappropriate for detection of all prostate cancers. The results need to be confirmed in other randomized trials.
Collapse
Affiliation(s)
- Seyyed Yousof Hosseini
- Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Atomic Energy Organization, Nuclear Research Center, Radioisotope Production Section, Tehran, Iran
| | | | | | | | | | | |
Collapse
|
37
|
Lange PH. Genitourinary oncology and its surgeon scientists: Triumphant past, but does it have a future? Urol Oncol 2007; 25:2-10. [PMID: 17208132 DOI: 10.1016/j.urolonc.2006.08.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Paul H Lange
- Department of Urology, University of Washington, Seattle, WA 98195, USA.
| |
Collapse
|
38
|
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24:3984-90. [PMID: 16921051 DOI: 10.1200/jco.2006.06.4246] [Citation(s) in RCA: 342] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa). Patients and Methods D2 PCa patients with baseline PSA of at least 5 ng/mL received 7 months induction AD. Patients achieving PSA of 4.0 ng/mL or less on months 6 and 7 are randomly assigned to continuous versus intermittent AD on month 8. Eligibility for this analysis required a prestudy PSA with at least two subsequent PSAs and that patients be registered at least 1 year before analysis date. Survival was defined as time to death after 7 months of AD. Associations were evaluated by proportional hazards regression models. Results One thousand one hundred thirty four of 1,345 eligible patients achieved a PSA of 4 ng/mL or less. At end of induction, 965 patients maintained PSA of 4 or less and 604 had a PSA of 0.2 ng/mL or less. After controlling for prognostic factors, patients with a PSA of 4 or less to more than 0.2 ng/mL had less than one third the risk of death (ROD) as those with a PSA of more than 4 ng/mL (P < .001). Patients with PSA of 0.2 ng/mL or less had less than one fifth the ROD as patients with a PSA of more than 4 ng/mL (P < .001) and had significantly better survival than those with PSA of more than 0.2 to 4 ng/mL or less (P < .001). Median survival was 13 months for patients with a PSA of more than 4 ng/mL, 44 months for patients with PSA of more than 0.2 to 4 ng/mL or less, and 75 months for patients with PSA of 0.2 ng/mL or less. Conclusion A PSA of 4 ng/mL or less after 7 months of AD is a strong predictor of survival. This data should be used to tailor future trial design for D2 prostate cancer.
Collapse
|
39
|
Abstract
For advanced prostate cancer - not including intermittent strategies - the patient is in continual treatment. The effect of the therapy must be controlled so that its failure can be determined as soon as possible and a new regimen started. As in most cases the progression of the disease can not be stopped, the aim of the therapy is to provide the patient with the best possible quality of life. In order to carry out therapy, if possible in the patient's usual environment, supportive therapies should be used, such as compensation for anaemia or pain therapy as required. Skeletal complications can be prophylactically treated by the use of biphosphonates.
Collapse
Affiliation(s)
- K Heine
- Urologische Klinik, Caritaskrankenhaus, Bad Mergentheim
| | | |
Collapse
|
40
|
Chiong E, Wong AFW, Chan YH, Chin CM. Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases. Asian J Surg 2005; 28:202-6. [PMID: 16024317 DOI: 10.1016/s1015-9584(09)60344-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
OBJECTIVE To review the pattern of initial clinical manifestation of patients who present with biochemically-advanced prostate carcinoma. METHODS A review of 39 prostate cancer patients with initial prostate specific antigen (PSA) levels of more than 400 ng/mL (study group) and 40 patients whose initial PSA levels were between 20 and 399 ng/mL (control group) was done. RESULTS The epidemiological profile and median Gleason score were similar in both groups. In the study and control groups, the median initial PSA levels were 1,000 ng/mL (range, 400-20,000 ng/mL) and 83 ng/mL (range, 21.8-337 ng/mL) respectively. Patients in the study group had statistically significantly higher incidences of bone pain, weight loss, loss of appetite, weakness in the lower limbs, and findings of abnormal prostate on digital rectal examination than patients in the control group. Significantly higher morbidity, including spinal cord compression, systemic lymphadenopathy, chronic urinary retention, elevated serum creatinine levels, anaemia and bone metastases, were also seen in the study group compared to the control group. Similar proportions of patients in the two groups developed hormone escape after treatment (50% in the study group, 45% in the control group). The cancer-specific mortality rate was 39.5% in the study group and 17.5% in the control group. CONCLUSION There is a high incidence of excess morbidity in patients who present with biochemically-advanced prostate carcinoma.
Collapse
Affiliation(s)
- Edmund Chiong
- Department of Surgery, National University of Singapore, Singapore.
| | | | | | | |
Collapse
|
41
|
Reflections on prostate cancer: personal experiences of two urologic oncologists. Prostate Cancer 2005. [DOI: 10.1201/b14450-68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
42
|
Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, Reuther AM, Klein EA. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004; 22:300-6. [PMID: 15283887 DOI: 10.1016/j.urolonc.2003.11.011] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2003] [Revised: 09/17/2003] [Accepted: 11/13/2003] [Indexed: 11/30/2022]
Abstract
Prostate-specific antigen (PSA) screening has resulted in a profound clinical stage migration. Extracapsular extension (ECE) presents a poor prognosis after radical prostatectomy (RP). In this study the trends in rate of ECE for cancers detected by PSA screening between 1987, when PSA screening became routine in the United States, and 2001, were examined. The clinical outcome of patients (total 1505; 888 clinical Tlc, 614 clinical T2, and 3 clinical T3) with prostate cancer diagnosed by PSA screening and treated with RP without neoadjuvant hormonal therapy was analyzed. The primary outcome variable was ECE rate with respect to year of treatment for a given tumor stage, preoperative PSA level, biopsy Gleason score, and surgical Gleason score. Logistic regression analysis was used to identify predictors of ECE. Biochemical relapse-free survival (bRFS) by year of treatment was analyzed by Kaplan-Meier Curve. Rate of ECE decreased from 65.8 to 25.2% during the 15-year study duration. Multivariate analysis of clinical tumor stage, age, preoperative serum PSA level, and Gleason score confirmed that year of treatment was an independent predictor of ECE. Six-year bRFS rates (by years of treatment) were 75.1% for 1987 to 1994 and 82.6% for 1995 to 2001 (P-value = 0.0022). PSA screening has resulted in a downward pathological stage migration. These observations demonstrate improved biochemical failure rates in more recently treated patients.
Collapse
Affiliation(s)
- Ithaar H Derweesh
- Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Khan MA, Partin AW. Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Curr Urol Rep 2004; 5:179-87. [PMID: 15161566 DOI: 10.1007/s11934-004-0035-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Since the late 1980s, early detection and monitoring of men for prostate cancer by serum prostate-specific antigen (PSA) measurement has resulted in an increase in the number of men presenting with a potentially curable disease. During the same time, in an attempt to provide a definitive cure, radical prostatectomy has been performed increasingly and now is regarded as the management option of choice for many patients with clinically localized prostate cancer. Radical prostatectomy involves the removal of all of the prostate tissue resulting in the serum PSA level to steadily decline to an undetectable level within 4 to 6 weeks after surgery. Despite improvements in surgical technique and a marked downward stage shift brought about by serum PSA testing, approximately 25% of men ultimately will experience a subsequent increase in serum PSA to a detectable level indicating disease recurrence after radical prostatectomy within 15 years. In this brief review, the factors associated with a high risk for disease recurrence after radical prostatectomy are discussed. Factors indicating whether the increasing serum PSA is caused by local recurrence or metastatic disease and the management options available to address serum PSA recurrence also are discussed.
Collapse
Affiliation(s)
- Masood A Khan
- James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Jefferson Building, Room 157, 600 North Wolfe Street, Baltimore, MD 21287-2101, USA
| | | |
Collapse
|
44
|
Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-86. [PMID: 15026333 DOI: 10.1158/0008-5472.can-03-3972] [Citation(s) in RCA: 355] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Aberrant DNA methylation patterns may be the earliest somatic genome changes in prostate cancer. Using real-time methylation-specific PCR, we assessed the extent of hypermethylation at 16 CpG islands in DNA from seven prostate cancer cell lines (LNCaP, PC-3, DU-145, LAPC-4, CWR22Rv1, VCaP, and C42B), normal prostate epithelial cells, normal prostate stromal cells, 73 primary prostate cancers, 91 metastatic prostate cancers, and 25 noncancerous prostate tissues. We found that CpG islands at GSTP1, APC, RASSF1a, PTGS2, and MDR1 were hypermethylated in >85% of prostate cancers and cancer cell lines but not in normal prostate cells and tissues; CpG islands at EDNRB, ESR1, CDKN2a, and hMLH1 exhibited low to moderate rates of hypermethylation in prostate cancer tissues and cancer cell lines but were entirely unmethylated in normal tissues; and CpG islands at DAPK1, TIMP3, MGMT, CDKN2b, p14/ARF, and CDH1 were not abnormally hypermethylated in prostate cancers. Receiver operator characteristic curve analyses suggested that CpG island hypermethylation changes at GSTP1, APC, RASSF1a, PTGS2, and MDR1 in various combinations can distinguish primary prostate cancer from benign prostate tissues with sensitivities of 97.3-100% and specificities of 92-100%. Hypermethylation of the CpG island at EDNRB was correlated with the grade and stage of the primary prostate cancers. PTGS2 CpG island hypermethylation portended an increased risk of recurrence. Furthermore, CpG island hypermethylation patterns in prostate cancer metastases were very similar to the primary prostate cancers and tended to show greater differences between cases than between anatomical sites of metastasis.
Collapse
Affiliation(s)
- Srinivasan Yegnasubramanian
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231-1000, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
This article discusses prostate-specific antigen (PSA) and screening for prostate cancer. Topics explored include the history of PSA testing, the biology of PSA, clinical uses of PSA testing, improving the accuracy of PSA testing, and controversies in prostate cancer screening.
Collapse
Affiliation(s)
- Misop Han
- Department of Urology, Feinberg School of Medicine, Northwestern University, 675 North St. Clair Street, Suite 20-150, Chicago, IL 60611, USA
| | | | | |
Collapse
|
46
|
Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004; 108:877-81. [PMID: 14712491 DOI: 10.1002/ijc.11639] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The objective of our study was to analyze the value of prostate-specific antigen (PSA) levels before and after androgen suppression to predict the time to androgen-independent progression (AIP) in patients with advanced and metastatic prostate cancer. A series of 283 prostate cancer patients under androgen suppression as a single treatment was studied. The disease was locally advanced in 98 patients and metastatic in the remainder 185. AIP was defined after 2 consecutive increases of serum PSA after the nadir value. The mean follow-up before AIP was 29.2 months (3-198). AIP was detected in 205 patients (72.4%). In 152 patients (74.1%), the event was detected within 24 months, while in 53 patients (25.9%), it was observed beyond 24 months. The multivariate analysis showed that the nadir PSA and the time to reach the nadir PSA were the most significant predictors of the time to AIP. The odds ratio of having a biochemical response greater than 24 months was 20 times higher in patients that achieved an undetectable PSA level of 0.2 ng/mL or less. Moreover in those patients whose nadir PSA reached beyond 12 months after androgen suppression the odds ratio was 18 times higher. These results show that the ability to achieve an undetectable nadir PSA and the time to reach it are the most significant predictors of the time to AIP in patients with locally advanced and metastatic prostate cancer under androgen suppression as a single therapy.
Collapse
Affiliation(s)
- Juan Morote
- Urology Department, Vall d'Hebron Hospital, Autònoma University of Barcelona, Po Vall d'Hebron 119-129, 08035 Barcelona, Spain.
| | | | | | | | | |
Collapse
|
47
|
Abstract
Prostate cancer that extends beyond the confines of the prostatic gland on clinical and/or radiographic assessment, without evidence of lymph node or distant metastases, is regarded as locally advanced. The locally advanced prostate cancer patient population consists of a heterogeneous group of men, some of whom have tumors that may be amenable to primary curative intent with local definitive therapy associated with acceptable long-term cancer control rates. In order to optimally manage this group of patients, it is important to be able to recognize who is at a high risk of tumor recurrence after primary local therapy. In this brief review, we discuss the factors that contribute to the prediction of high risk in populations with locally advanced disease and the treatment options available.
Collapse
Affiliation(s)
- Masood A Khan
- James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
| | | |
Collapse
|
48
|
|
49
|
Lisek EW, Elterman L, McKiel CF, Hoeksema J. Prostate Cancer. Surg Oncol 2003. [DOI: 10.1007/0-387-21701-0_49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
50
|
Erasmus CE, Verhagen WIM, Wauters CAP, van Lindert EJ. Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci 2002; 29:375-7. [PMID: 12463494 DOI: 10.1017/s0317167100002250] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Symptomatic brain metastases from prostatic carcinoma are rare (0.05% to 0.5%). CASE REPORT A 70-year-old man presented with a homonymous hemianopsia due to brain metastatic prostatic carcinoma shortly before becoming symptomatic of prostatic disease. CT and MRI of the brain showed a tumour deep in the right hemisphere near the thalamus and involving the optic radiation. RESULTS Routine haematological and biochemical tests were normal. The prostate specific antigen level was low on two separate occasions. The prostatic and brain tumours showed identical appearances, namely of a poorly differentiated adenocarcinoma with neuroendocrine differentiation (small cell carcinoma). CONCLUSION A literature review suggests that small cell carcinoma of the prostate is more likely to spread to the brain compared to adenocarcinoma and that brain metastases indicate a poor prognosis. The prostate gland should be remembered as a possible cause of brain metastases and that a normal serum prostate specific antigen does not exclude this diagnosis.
Collapse
Affiliation(s)
- Corrie E Erasmus
- Department of Neurosurgery, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | | | | | | |
Collapse
|